“`html
Motor Neuron Disease (MND) Clinical Trial
Background
People with MND often experience high psychological distress due to the progressive nature of the disease. This study aimed to assess the cost-effectiveness of acceptance and commitment therapy (ACT) tailored for MND patients in improving their quality of life.
Methods
- Compared ACT plus usual care with usual care alone over 9 months
- Used health utilities from EQ-5D-5L questionnaire to calculate quality-adjusted life years (QALYs)
- Conducted sensitivity and subgroup analyses
Results
- Intervention costs drove the statistically significant difference in total costs between the two groups
- No statistically significant difference in effects measured by EQ-5D-5L
- Incremental cost-effectiveness above the £20,000 to £30,000 per QALY gained threshold
- Statistically significant difference in effects measured by the McGill Quality of Life-Revised (MQOL-R) questionnaire
- Cost-effective for subgroup with medium deterioration in motor neuron symptoms
Conclusions
Despite being cost-ineffective in the primary analysis, the significant improvement in quality of life measured by MQOL-R, low intervention costs, positive subgroup analysis results, and overall improvement in MND patients’ quality of life suggest that ACT could be beneficially integrated into MND clinical services.
For full clinical trial report, click here.
“`
